ATRA Stock Analysis: Buy, Sell, or Hold?
ATRA - Atara Biotherapeutics, Inc
$8.04
-0.63 (-7.27%)
▼
5d:
-21.64%
30d:
-23.14%
90d:
+64.42%
WAIT
LOW Confidence
Analysis Updated: Jul 14, 2026 12:00 AM ET
Earnings: Aug 10, 2026
25d
Get Alerted When ATRA Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
⏸️ WAIT FOR STABILIZATION: ATRA is down 21.6% over the last 5 days. While fundamentals may be solid, catching a falling knife is risky. Wait for price to stabilize before entering.
⏸️ WAIT FOR STABILIZATION: ATRA is down 21.6% over the last 5 days. While fundamentals may be solid, catching a falling knife is risky. Wait for price to stabilize before entering.
Long-Term Wealth Forecast (2031)
Based on Analyst Consensus Growth & Historical Valuation
0% (Stagnation)
50% (Hyper Growth)
EST. PRICE IN 2031
$29.36
Based on 7.0% avg growth
INTRINSIC VALUE TODAY
$18.23
55.9% Margin of Safety
How this is calculated: We use a Growth Decay Model: starting with analyst consensus growth (adjusted above) and gradually slowing it down to a long-term terminal rate (4%) by Year 5. This provides a more realistic valuation than assuming constant hyper-growth. We then apply a 16.5x Exit PE.
In-depth Analysis How we analyze
Valuation Analysis: ATRA is currently trading at $8.04, which is considered oversold relative to its 30-day fair value range of $9.39 to $11.01. From a valuation perspective, the stock is trading at a discount (Forward PE: 6.3) compared to its historical average (16.5). Remarkably, the market is currently pricing in an annual earnings decline of 27.3% over the next few years. This aligns with recent fundamental challenges.
Technical Outlook: Technically, ATRA is in a strong uptrend. The price is currently testing key support at $7.91. A bounce from this level would confirm strength, while a break below could signal further downside. Short-term momentum is weak, with the stock down 7.3% recently.
Market Sentiment: The stock shows a mixed technical setup (40/100), with neutral trendline and momentum signals. Wall Street analysts see significant upside, with an average price target of $13.67 (+70.0%). Current signals suggest waiting for a better entry point before initiating new positions.
Technical Outlook: Technically, ATRA is in a strong uptrend. The price is currently testing key support at $7.91. A bounce from this level would confirm strength, while a break below could signal further downside. Short-term momentum is weak, with the stock down 7.3% recently.
Market Sentiment: The stock shows a mixed technical setup (40/100), with neutral trendline and momentum signals. Wall Street analysts see significant upside, with an average price target of $13.67 (+70.0%). Current signals suggest waiting for a better entry point before initiating new positions.
Quick Decision Summary
Current Position
OVERSOLD
Historical Trading Range
$9.39 -
$11.01
Company Quality Score
50/100
(HOLD)
Volume Confirmation
HIGH
Confidence Score
74.8%
All Signals
- BULLISH: Price oversold vs 30-day range
- NEUTRAL: Mixed technical signals (40/100)
- BULLISH: High volume confirmation
- BEARISH: Downward momentum (-7.3%)
- BULLISH: Trading 70.0% below Wall St target ($13.67)
- WARNING: Recommendation downgraded due to -21.6% 5-day decline - wait for stabilization
Trading Range Analysis
30-Day Trading Range
$9.39 -
$11.01
Current vs Trading Range
OVERSOLD
Support & Resistance Levels
Support Level
$7.91
Resistance Level
$12.00
Current Trend
Strong Uptrend
Technical data as of
Jul 14, 2026
Fundamental Context
Forward P/E (Next Year Est.)
6.33
Wall Street Target
$13.67
(+70.0%)
Revenue Growth (YoY)
-99.5%
Profit Margin
-40.9%
Valuation Discount vs History
-27.3% cheaper
PE vs Historical
6.3 vs 16.5
CHEAP
Market-Implied Price Targets
If current PE multiple persists
Implied Growth (YoY):
-27.3%
(market-implied from PE analysis)
1-Year Target
$7.24
(-10%)
2-Year Target
$6.51
(-19%)
3-Year Target
$5.86
(-27%)
3-Yr Target (if PE normalizes)
(PE: 6→17)
$15.28
(+90%)
💡
Upside Surprise Potential
If earnings stabilize (0% growth), PE could expand from 6.3 to 16.5
Stabilization Target:
$20.96
(+160.6%)
PE Expansion Potential:
+160.6%
Share & Embed Analysis
Last updated: July 14, 2026 10:18 PM ET
Data refreshes hourly during market hours. Next update: 11:18 PM
Data refreshes hourly during market hours. Next update: 11:18 PM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is ATRA showing a specific setup today?
Insider Activity (6 Months)
0
Buys
0
Sells
0
Net
NEUTRAL
Top Rated Biotechnology Stocks
Top-rated stocks in Biotechnology by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
VRTX
Vertex Pharmaceuticals I… |
BUY
34 analysts |
$555 | 51 HOLD |
|
XENE
Xenon Pharmaceuticals Inc |
STRONG BUY
19 analysts |
$81 | 55 HOLD |
|
CYTK
Cytokinetics Inc |
STRONG BUY
21 analysts |
$108 | 57 HOLD |
|
MLTX
MoonLake Immunotherapeut… |
STRONG BUY
16 analysts |
$28 | 62 BUY |
|
INCY
Incyte Corporation |
HOLD
27 analysts |
$111 | 60 HOLD |
